Published in J Clin Invest on November 01, 2003
Th17 cells in human disease. Immunol Rev (2008) 4.27
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest (2004) 2.34
Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis (2005) 2.24
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest (2012) 1.58
Keratinocyte apoptosis in epidermal development and disease. J Invest Dermatol (2006) 1.28
Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis. Am J Pathol (2006) 1.24
Cerebral interleukin-15 shows upregulation and beneficial effects in experimental autoimmune encephalomyelitis. J Neuroimmunol (2010) 1.20
IL-15: a central regulator of celiac disease immunopathology. Immunol Rev (2014) 1.14
Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech (2012) 1.09
Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia. Proc Natl Acad Sci U S A (2005) 1.06
Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22. J Invest Dermatol (2008) 1.04
NK cells and psoriasis. J Biomed Biotechnol (2011) 0.97
Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab. MAbs (2014) 0.97
Lack of IL-15 results in the suboptimal priming of CD4+ T cell response against an intracellular parasite. Proc Natl Acad Sci U S A (2006) 0.96
Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases. Arthritis Res Ther (2004) 0.95
IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction. Nat Rev Immunol (2015) 0.94
Serum levels of selected Th17 and Th22 cytokines in psoriatic patients. Dis Markers (2013) 0.91
Serum cytokine and chemokine profiles in patients with myasthenia gravis. Clin Exp Immunol (2014) 0.90
Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin. BMC Dermatol (2011) 0.88
Novel identified receptors on mast cells. Front Immunol (2012) 0.88
Comparison of the effects of vitamin D products in a psoriasis plaque test and a murine psoriasis xenograft model. J Transl Med (2009) 0.87
The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res (2007) 0.84
Epidermal IL-15Rα acts as an endogenous antagonist of psoriasiform inflammation in mouse and man. J Exp Med (2013) 0.83
Fas pulls the trigger on psoriasis. Am J Pathol (2006) 0.82
Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med Mol Imaging (2004) 0.82
Interleukin 15 primes natural killer cells to kill via NKG2D and cPLA2 and this pathway is active in psoriatic arthritis. PLoS One (2013) 0.82
Leukotoxin kills rodent WBC by targeting leukocyte function associated antigen 1. Comp Med (2013) 0.81
Soluble interleukin-15 complexes are generated in vivo by type I interferon dependent and independent pathways. PLoS One (2015) 0.78
Active immunization with human interleukin-15 induces neutralizing antibodies in non-human primates. BMC Immunol (2016) 0.76
IL-15 receptor α signaling constrains the development of IL-17-producing γδ T cells. Proc Natl Acad Sci U S A (2015) 0.76
Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo. Br J Pharmacol (2011) 0.76
Blockade of B-cell activating factor with TACI-IgG effectively reduced Th1 and Th17 cells but not memory T cells in experimental allergic encephalomyelitis mice. Cent Eur J Immunol (2015) 0.75
NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27. Oncotarget (2017) 0.75
miR-15b is Downregulated in Myasthenia Gravis Patients and Directly Regulates the Expression of Interleukin-15 (IL-15) in Experimental Myasthenia Gravis Mice. Med Sci Monit (2015) 0.75
Modeling the pharmacokinetic-pharmacodynamic relationship of the monoclonal anti-macaque-IL-15 antibody Hu714MuXHu in cynomolgus monkeys. Pharmacol Res Perspect (2016) 0.75
Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 83.56
Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science (1994) 6.65
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 6.49
IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity (2002) 6.10
Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med (1994) 5.20
Interleukin 15: biology and relevance to human disease. Blood (2001) 4.47
Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med (1997) 4.03
The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol (1999) 3.81
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 3.19
The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med (1996) 2.99
Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood (1996) 2.62
A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest (1997) 2.37
Interleukin-15 protects from lethal apoptosis in vivo. Nat Med (1997) 2.22
Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med (1995) 2.09
High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol (1996) 2.07
The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol (1993) 2.04
Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol (1994) 1.83
Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood (1999) 1.71
T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol (1994) 1.62
Animal models of psoriasis - what can we learn from them? J Invest Dermatol (1999) 1.58
Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol (1999) 1.57
Interleukin-2, interleukin-15, and their receptors. Int Rev Immunol (1998) 1.56
Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol Today (1998) 1.53
Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J Immunol (2000) 1.29
UM4D4+ (CDw60) T cells are compartmentalized into psoriatic skin and release lymphokines that induce a keratinocyte phenotype expressed in psoriatic lesions. J Invest Dermatol (1990) 1.29
Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol (1997) 1.23
Retracted The IL-15R alpha chain signals through association with Syk in human B cells. J Immunol (2001) 1.20
Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci (2000) 1.15
Creation of psoriatic plaques: the ultimate tumor suppressor pathway. A new model for an ancient T-cell-mediated skin disease. Viewpoint. J Cutan Pathol (2001) 1.13
Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol (1995) 1.04
T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation. J Invest Dermatol (1993) 1.03
Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun (1997) 1.02
Discordant expression of Bcl-x and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am J Pathol (1995) 1.00
Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling. J Biol Chem (1997) 0.98
Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors. J Invest Dermatol (2002) 0.95
Dermal fibroblasts sustain proliferation of activated T cells via membrane-bound interleukin-15 upon long-term stimulation with tumor necrosis factor-alpha. J Invest Dermatol (2001) 0.95
Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. J Investig Dermatol Symp Proc (2000) 0.95
Decreased IL-15 may contribute to elevated IgE and acute inflammation in atopic dermatitis. J Immunol (2002) 0.92
Interleukin-15 activates proinflammatory and antimicrobial functions in polymorphonuclear cells. Infect Immun (1998) 0.91
1alpha,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J Invest Dermatol (1999) 0.89
Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol (1998) 0.88
Interleukin-15 and its role in chronic inflammatory diseases. Inflamm Res (1998) 0.87
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med (2009) 5.87
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol (2006) 4.72
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science (2007) 4.52
An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol (2008) 3.75
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol (2006) 3.59
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood (2004) 3.38
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood (2011) 2.96
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol (2010) 2.51
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum (2005) 2.37
Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol (2003) 2.34
Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J (2011) 2.30
Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol (2013) 2.18
Development of atopic dermatitis during the first 3 years of life: the Copenhagen prospective study on asthma in childhood cohort study in high-risk children. Arch Dermatol (2006) 2.16
Contrasting IgG structures reveal extreme asymmetry and flexibility. J Mol Biol (2002) 2.10
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol (2002) 2.06
The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol (2004) 2.02
Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. J Neurosci (2009) 1.97
Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol (2005) 1.95
IgG4 breaking the rules. Immunology (2002) 1.93
Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. J Neuroinflammation (2008) 1.92
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol (2009) 1.90
Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol (2003) 1.84
Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum (2002) 1.79
Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis (2003) 1.73
Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol (2009) 1.71
Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes (2002) 1.67
Crosstalk between human IgG isotypes and murine effector cells. J Immunol (2012) 1.53
Complement is activated by IgG hexamers assembled at the cell surface. Science (2014) 1.52
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica (2010) 1.49
Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol (2008) 1.46
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A (2013) 1.42
Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant (2007) 1.41
A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol (2008) 1.40
Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res (2006) 1.39
Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res (2009) 1.39
Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol (2004) 1.39
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood (2008) 1.38
Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol (2007) 1.38
In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res (2010) 1.37
The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther (2009) 1.35
Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J Immunol (2011) 1.34
STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle (2013) 1.33
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res (2008) 1.30
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med (2008) 1.26
MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci (2010) 1.24
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs (2015) 1.16
Dlk1/FA1 is a novel endocrine regulator of bone and fat mass and its serum level is modulated by growth hormone. Endocrinology (2007) 1.16
Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol (2011) 1.16
Functional characteristics of the high affinity IgG receptor, FcγRI. J Immunol (2011) 1.15
When binding is enough: nonactivating antibody formats. Curr Opin Immunol (2008) 1.15
Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood (2012) 1.15
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood (2007) 1.14
IL-23 and T(H)17-mediated inflammation in human allergic contact dermatitis. J Allergy Clin Immunol (2008) 1.14
Therapeutic antibody gene transfer: an active approach to passive immunity. Mol Ther (2004) 1.14
IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol (2008) 1.14
Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol (2012) 1.12
Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. J Mol Biol (2007) 1.11
Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol (2003) 1.10
Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol (2011) 1.10